

KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED

(A Government of India Enterprise)

ENQUIRY REF. No.	KAPL/QAD/020/0375
DATE	03/06/2025
DUE DATE	09/06/2025(13.00HRS)

Dear Sir,

Please submit your lowest and competitive offer in a SEALED ENVELOPE, DULY SUPERSCRIBING OUR ABOVE ENQUIRY REF. NO., DATE and DUE DATE on it/ OR MAIL, with other details of F.O.R terms, Taxes, Credit period, Delivery offered, Name of the Make, Detailed Specification etc., for below mentioned material/s

	SL. NO.	ITEM CODE	ITEM DESCRIPTION	UOM	QTY.
Ì	01	OFD070	NUCLEOSIL C18 COLUMN 100A,5µM,4.6MMX25CM	NOS	02

OTHER TERMS:

1. F.O.R TERMS

2. GST %

3. PACKING & FORWARDING CHARGES

4. CREDIT PERIOD

5. DELIVERY OFFERED

: DOOR DELIVERY

: PLEASE SPECIFY

: NOT APPLICABLE

: 30 DAYS

NOTE: IN CASE YOU ARE NOT QUOTING PLEASE SEND THE REGRET LETTER.

Thanking you,

Yours faithfully, For KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED

YUVARAJA M

DEPUTY MANAGER PURCHASE DEPT

MAKE - MACHERY - NAREL



KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LIMITED, BENGALURU

RESEARCH AND DEVELOPMENT

User Requirement Specifications

Material Description: NUCLEOSIL C18 Column 100Å, 5 μ m, 4.6 mm X 25 cm

URS Number: RD/URS/010/0425/V1

1. Description and Quantity

Material DescriptionNUCLEOSIL C18 Column 100Å, 5 μm, 4.6 mm X 25 cmItem CodeQFD070Quantity/Box1

2. User Specifications

#	Requirement	Specification
1,	Detailed Description	EC HPLC column EC 250/4.6 NUCLEOSIL 100-5 C18 length: 250 mm, ID: 4.6 mm pack of 1
2.	Make	Macherey-Nagel
3.	Brand	Nucleosil
4.	Part No.	MN-720014.46
5.	Matrix active group	C18 (RP-18, ODS, Octadecyl)
6.	Particle size	5 μm
7,	Surface Area (m ² /g)	350.0
8.	Length	25 cm
9.	Internal Diameter (I.D.)	4.6 mm
10.	Pore Size	100 Å
11.	Particle Substrate	Silica
12.	Particle Shape	Spherical, fully porous
13.	External Construction Materials	Stainless Steel
14.	Endcapped	YES
15.	USP Classification	L1
16.	Separation Mode	Reversed Phase Chromatography (RP)
17.	pH Range	2-8
18.	Maximum Pressure	400 bar pressure (5801 psi)
19.	Age of Column	Must be no more than 24 months old at the time of delivery

Tramadol Injection

Action and use

µ-Opioid receptor (OP3, MOR) agonist and noradrenaline reuptake inhibitor; analgesic.

DEFINITION

Tramadol Injection contains Tramadol Hydrochloride.

The Injection complies with the requirements stated under Parenteral Preparations and with the following requirements.

Content of tramadol hydrochloride, C16H25NO2, HCl 95.0 to 105.0% of the stated amount.

IDENTIFICATION

In the Assay, record the UV spectrum of the principal peak in the chromatograms obtained with solutions (1) and (2) with a diode array detector in the range of 210 to 400 nm.

The UV spectrum of the principal peak in the chromatogram obtained with solution (1) is concordant with that of the peak in the chromatogram obtained with solution (2); the retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that of the peak in the chromatogram obtained with solution (2).

TESTS

Acidity or alkalinity

pH of a solution containing 5% w/v of Tramadol Hydrochloride, 6.0 to 7.0, Appendix V L.

Clarity and colour of solution

The injection is clear, Appendix IV A, and colourless, Appendix IV B, Method I.

Related substances

Carry out the method for liquid chromatography, Appendix III D, using the following solutions.

- (1) Dilute the injection with sufficient mobile phase to produce a solution containing 0.05% w/v of Tramadol Hydrochloride.
- (2) Dilute 1 volume of solution (1) to 50 volumes with the mobile phase and further dilute I volume to 10 volumes with the mobile phase.
- (3) 0.005% w/v each of tramadol hydrochloride BPCRS and tramadol impurity A BPCRS in the mobile phase.

CHROMATOGRAPHIC CONDITIONS

- (a) Use a stainless steel column (25 cm × 4.6 mm) packed with end-capped octadecylsilyl silica gel for chromatography (5 μm) (Nucleosil 100-5 C18 is suitable).
- (b) Use isocratic elution and the mobile phase described
- (c) Use a flow rate of 1.0 mL per minute.
- (d) Use an ambient column temperature.
- (e) Use a detection wavelength of 270 nm.
- (f) Inject 20 μL of each solution.
- (g) For solution (1) allow the chromatography to proceed for five times the retention time of the principal peak.

MOBILE PHASE

295 volumes of acetonitrile and 705 volumes of 0.2% w/v of trifluoroacetic acid.

SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity A and tramadol is at least 3.0.

CALCULATION OF IMPURITIES

For each impurity, use the concentration of tramadol hydrochloride in solution (2).

For the reporting threshold, use the concentration of tramadol hydrochloride in solution (2).

Tramadol retention time: about 5 minutes.

Relative retention: impurity D, about 0.7; impurity A, about 0.9; impurity 1, about 1.2; impurity 2, about 1.9; impurity C, about 2.4; impurity B, about 2.7 and impurity 3,

LIMITS

- unspecified impurities: for each impurity, not more than
- total impurities: not more than 1.0%;
- reporting threshold: 0.1%.

ASSAY

Carry out the method for liquid chromatography, Appendix III D, using the following solutions.

- (1) Dilute the injection with sufficient mobile phase to produce a solution containing 0.05% w/v of Tramadol Hydrochloride.
- (2) 0.05% w/v of tramadol hydrochloride BPCRS in the mobile phase.
- (3) 0.005% w/v each of tramadol hydrochloride BPCRS and tramadol impurity A BPCRS in the mobile phase.

The chromatographic conditions described under Related substances may be used.

SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity A and tramadol is at least 3.0.

DETERMINATION OF CONTENT

Calculate the content of C₁₆H₂₅NO₂,HCl in the injection from the chromatograms obtained and using the declared content of C₁₆H₂₅NO₂,HCl in tramadol hydrochloride BPCRS.

IMPURITIES

The impurities limited by the requirements of this monograph include impurities A to D listed under Tramadol Hydrochloride and:

1. (1RS,2RS)-2-[(dimethylamino)methyl]-1-(3methoxyphenyl)cyclohexanol N-oxide

2. 8a-(3-methoxyphenyl)-3-methyloctahydro-2H-1,3benzoxazine











Home


> EC HPLC column EC 250/4.6 NUCLEOSIL 100-5 C18 length: 250 mm, ID: 4.6 mm pack of 1



EC HPLC column EC 250/4.6 NUCLEOSIL 100-5 C18 length: 250 mm, ID: 4.6 mm pack of 1

Part Number: MN-720014.46
Manufacturer: Macherey-Nagel





Request a quote



length: 250 mm, ID: 4.6 mm pack of 1

(i) Product Line

→ Nucleosil

Product details	Support-Downloads	
EC HPLC column EC 250/4.6 NUCLEOSIL 1		-5 C18

Quantity 1 Stk.

Manufacturer Macherey-Nagel

Brand Nucleosil

Product Type HPLC Column

Length 250 mm

Internal Diameter 4.6 mm

Particle Size 5 μm

C18 (RP-18, ODS, Octadecyl)

Chemistry
Producers Term

Pore Size 100 Å

USP Class L1

Carbon Load 15.0 %

Bet Surface Area

350.0

Endcapping

endcapped

Country of Origin

Germany

Column Type

Analytical Column

Hardware Material

Stainless Steel

Hardware Type

Ready-to-use Column

pH Minimum

2.0

pH Maximum

8.0

Temperature

Maximum [°C]

60

Mode of Separation Reversed Phase Chromatography (RP)

Technology

HPLC

Matrix

Silica

Particle Morphology spherical, fully porous

Pressure Stability

400 bar



Subscribe to the newsletter of MZ-Analysentechnik GmbH

Please insert your e-mail address...

Subscribe now



MZ-Analysentechnik GmbH

Barcelona-Allee 17

D-55129 Mainz

Tel: +49-6131-88096-0

Products

Manufacturer Overview

Brand Overview

HPLC Column Selector

Applications

Catalogues and Brochures

News







Special Offers

Shop

My Account

Shipping & Payment Methods

FAQ

Company

About us

DIN ISO 9001

Code of Conduct

Career

Contact us

MZ-Analysentechnik GmbH has been a manufacturer of HPLC and GPC columns and a supplier of chromatography columns and accessories since 1986. The company has implemented an internal compliance program and a quality management system with DIN ISO 9001:2015 certification. The product range includes more than 125 manufacturers with more than 220,000 products in the online store.



Terms and Conditions
© 2024 MZ-Analysentechnik GmbH

Privacy Policy

Imprint